Skip to main content
NewslettersWatchlist

Achieve Life Sciences Inc(ACHV-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low4.45
Day High4.54
Open:4.52
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
GlobeNewswire
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
GlobeNewswire
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
GlobeNewswire
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
GlobeNewswire
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
The Globe and Mail
Short sales on the TSX: What bearish investors are betting against
Globe Newswire
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
Globe Newswire
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Globe Newswire
Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference
Globe Newswire
Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
AccessWire
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
Globe Newswire
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
Globe Newswire
Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update
Globe Newswire
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
Globe Newswire
Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors
Globe Newswire
Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award
Globe Newswire
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update
Globe Newswire
Achieve Life Sciences Announces Participation in March Investor Conferences
Globe Newswire
Achieve Life Sciences Announces Participation in February Investor Conferences
AccessWire
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
Globe Newswire
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Globe Newswire
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Globe Newswire
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Globe Newswire
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development
Globe Newswire
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
Globe Newswire
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Globe Newswire
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
Globe Newswire
Achieve Life Sciences Announces Participation in November Investor Conferences
Globe Newswire
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
AccessWire
Achieve Life Sciences to Participate in Upcoming Investor Conferences
AccessWire
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

Profile

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.